- Study Demonstrates Highly Accurate Performance Of The Test Allowing To Decrease Largest Number Of Avoidable Diagnostic Thyroid Surgeries
NEW YORK, Oct. 9, 2017 /PRNewswire/ -- ThyroSeq®, a joint partnership between UPMC and CBLPath, announced today, that the results of a double-blind, multi-center international study, validating the performance of ThyroSeq V3® in thyroid nodules with indeterminate cytology, will be presented at the 87th Annual Meeting of the American Thyroid Association (ATA). The meeting will be held on October 18-22 in Victoria, BC, Canada. A clinical oral presentation and a poster presentation will demonstrate ThyroSeq’s V3 effective tools for a definitive diagnosis and ability to decrease the largest number of avoidable diagnostic surgeries, thus providing the most cost-effective patient care.
“We are excited to have the opportunity to present our findings demonstrating the performance of this new, most comprehensive version of ThyroSeq for diagnosis of cancer in thyroid nodules,” said Yuri Nikiforov, M.D., Ph.D, Professor of Pathology at University of Pittsburgh Medical Center, and principal investigator of the multi-center ThyroSeq V3 trial. “The results of rigorous test validation in multiple clinical centers in the U.S. and abroad provide confidence that this most accurate test will allow us to save the largest number of avoidable thyroid surgeries and offer individualized management of patients with thyroid nodules and cancer based on the cutting-edge genomic science.”
Clinical oral presentation and poster presentation are as follows:
Title: | Results of the multi-institutional prospective double blind study of ThyroSeq V3 performance in thyroid nodules with indeterminate cytology. |
Presenters: | Steven Hodak, M.D., NYU Langone Medical Center |
Yuri Nikiforov, M.D., Ph.D, University of Pittsburgh Medical Center | |
Bryan Haugen, M.D., University of Colorado | |
Date/Time: | THURSDAY, OCTOBER 19, Noon - 1:00 PM |
Location: | Victoria Conference Center, Oak Bay |
Title: | Analytical Performance of the ThyroSeq V3 Genomic Classifier for Cancer Diagnosis in Thyroid Nodules |
(ShortCall Poster Presentation) | |
Presenters: | Marina N. Nikiforova, M.D., University of Pittsburgh Medical Center, et al. |
Date/Time: | FRIDAY, OCTOBER 20, 9:30-10:45 AM; 3:00 PM - 4:30 PM |
Location: | Victoria Conference Center, ATA Exhibit Hall |
Title: | Clinical Validation of ThyroSeq V3 Performance in Thyroid Nodules with Indeterminate Cytology: |
A Prospective Blinded Multi-Institutional Validation Study | |
(Clinical Short Call Oral Presentation) | |
Presenters: | Yuri Nikiforov, M.D., Ph.D, University of Pittsburgh Medical Center, et al. |
Date/ Time: | SATURDAY, OCTOBER 21, 8:00 AM - 9:30 AM |
Location: | Victoria Conference Center, Salon AB |
About ThyroSeq
ThyroSeq is a joint partnership between UPMC and CBLPath. ThyroSeq is an innovative test for thyroid nodules and cancer. With a 10-year history of continuous refinement, it incorporates all major scientific discoveries and utilizes advanced technology to provide the most accurate diagnosis of benign or malignant disease in thyroid nodules. For more information, visit ThyroSeq online.
About CBL Pathology
CBLPath, Inc. is a leading provider of sub-specialized anatomic pathology and molecular diagnostic laboratory services. For more information, please visit www.cblpath.com
Jeanine Wilson
(845) 548-1211
thyroseq@wmediagroup.com
View original content with multimedia:http://www.prnewswire.com/news-releases/thyroseq-announces-results-of-large-multi-center-international-study-validating-new-thyroseq-v3-test-to-be-presented-at-american-thyroid-association-annual-meeting-300533441.html
SOURCE ThyroSeq
